MetaCap

Altimmune (ALT) vs Prelude Therapeutics (PRLD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Prelude Therapeutics (PRLD) has outperformed Altimmune (ALT) over the past year, gaining 93.4% versus a loss of 72.3%. Over five years, PRLD leads with a -76.9% price change compared with -87.2% for ALT. Altimmune is the larger company by market cap ($258.8 million vs $258.6 million), about 1.0 times the size.

Prelude Therapeutics converts more of its revenue into profit, with a net margin of -819.6% versus -214861.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALT-72.35%PRLD+93.41%
+315%+112%-91%
Nov 21, 20251 yearNov 20, 2026
ALT-87.39%PRLD-77.66%
+123%+9%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALT versus PRLD key metrics
MetricALTPRLD
Share price$1.33$3.23
Market cap$258.80M$258.63M
1-day change-5.67%-0.77%
YTD return-63.16%+11.38%
1-year return-72.35%+93.41%
5-year return-87.24%-76.93%
EPS (TTM)$-0.71$-0.59
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$41.00K$12.14M
Revenue growth (YoY)+105.00%+73.43%
Net income (latest FY)$-88.09M$-99.50M
Operating margin-230460.98%-861.33%
Net margin-214860.98%-819.59%
52-week high$6.44$6.83
52-week low$1.32$1.30
Distance from 52-week high-79.35%-52.71%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1127.82%+172.45%
Average volume3.91M432.74K
Shares outstanding194.59M65.34M
Employees5779
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PRLD has outperformed ALT by 165.8 percentage points over the past year.
  • Prelude Therapeutics is more profitable, keeping -819.6 cents of every revenue dollar as net income versus -214861.0 cents for Altimmune.
  • Altimmune grew revenue faster in its latest fiscal year (+105.00% vs +73.43%).

About Altimmune

ALT stock →

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees

About Prelude Therapeutics

PRLD stock →

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.

Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees

ALT vs PRLD FAQ

Which is bigger, Altimmune or Prelude Therapeutics?

Altimmune (ALT) is larger, with a market capitalization of $258.80M compared with $258.63M for Prelude Therapeutics (PRLD).

Which stock has performed better over the past year, ALT or PRLD?

PRLD returned +93.41% over the past 12 months, compared with -72.35% for ALT (price return, excluding dividends). Past performance does not predict future results.

Are Altimmune and Prelude Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons